LETTER TO THE EDITOR

Treating the Hodgkin's
Lymphoma Variant of Richter's
Transformation

monitoring during CLL treatment, especially with purineanalogs, and reduction with antivirals to reduce EBVassociated RT is another plausible, albeit debatable
approach.3

Sir,

Golden et al. from Dublin, Ireland recently reported a
case of Hodgkin's lymphoma (HL) arising from Richter's
transformation (RT) in an elderly gentleman with chronic
lymphocytic leukemia (CLL).1 RT into aggressive nonHodgkin's lymphoma (NHL) is a well-documented
occurrence; however, HL arising from RT occurs in only
0.5% of patients and carries a poorer prognosis than
de novo HL.2 Given its rarity, the optimal treatment for
this disease has not been systematized with most data
limited to isolated patients or patient-series.

Commonly used regimens are ABVD, MOPP and CVPP.
These regimens have been used with or without
concurrent radiotherapy in the HL variant of RT (HL-RT).
Regimens for aggressive NHL have also been used.
Overall, these have shown < 50% response rates, with
short overall survival (up to 1.7 years).2 Detailed
analyses for ABVD and MOPP regimens show only
27.3% complete response (CR) rates.3 CLL (and
therefore, HL-RT) is a disease of the elderly. Elderly
patients generally have several comorbidities such as
kidney and liver diseases (with impaired metabolism and
clearance of drugs), cardiovascular diseases and frailty.
These factors make toxicities major concerns that limit
treatment options and adversely affect survival; hence
treatment regimens need to be selected carefully,
weighing the benefits over adverse effects.4 Highly
aggressive therapies, such as stem cell transplantation,
are not suitable for elderly patients, such as the one
discussed,1 and have failed to show promise even in
younger HL-RT patients who are suitable candidates.2
Prior treatment with purine-analogs, consequent
reduction of cell-mediated immunity and reactivation of
latent Epstein-Barr virus (EBV) are better predictors of
RT and aggressive HL than poor-risk molecular/
biological factors.3 Considering that a vast majority of
patients with HL-RT are positive for EBV, the virus is
believed to be a transforming agent, playing a crucial
role in the pathogenesis of RT, especially in case of the
HL variant.2 This represents a potential biological factor
for targeted therapy to improve outcomes. In in vivo
studies, histone deacetylase (HDAC) inhibitors have
shown to induce viral thymidine-kinase expression,
sensitizing EBV+ lymphoma cells to nucleoside
antivirals and showing significant activity against EBVassociated lymphomas.2,4 Incorporating EBV viral-load
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Reed-Sternberg cells in nodular-lymphocyte-predominant
HL are CD20+ as opposed to only 20% of classical HL
cases showing CD20-positivity. Given that CLL cells are
also CD20+, anti-CD20 monoclonal antibodies (like
rituximab or ofatumumab) used in combination with
other agents, may be reasonable options for CD20+
HL-RT.3

Brentuximab Vedotin (BV) is an anti-CD30 antibodydrug conjugate showing activity against HL, even in
elderly patients. Able to produce notable responses in
up to 75% patients (CR: 34%), the only notable adverse
effect associated with BV is peripheral neuropathy,
which is reversible in 50% of patients after discontinuing
treatment. Bendamustine is another agent that has
shown better tolerability in elderly HL patients,
showing responses in 58% heavily-pretreated patients
(CR: 33%). Based on these reports, BV and
bendamustine are promising agents for treating de novo
HL in elderly patients. Although not currently, but in the
future, these agents may become therapeutic options for
HL-RT, potentially showing both efficacy and tolerability
with improving outcomes in this patient group.2,4

In a developing country like Pakistan, treatment is
limited by non-availability or high costs of different
agents. HDAC inhibitors and ofatumumab are not
available in the country. While BV and rituximab are
available at several centers, their high cost makes them
inaccessible to a vast majority of patients. Patients
should be screened for positivity against EBV.
Monitoring EBV viral-load during CLL treatment and
therapy with antiviral medications, if positive, may prove
to be a cost-effective and efficient strategy to reduce the
risk of RT (both HL and NHL) in CLL patients. Since
bendamustine is a relatively less costly and efficacious
drug showing good tolerability, especially in elderly
patients,5 novel chemotherapy regimens containing
bendamustine or combining it with other drugs from
conventional HL regimens, may prove to be beneficial in
treating patients with HL-RT. Since HL-RT is a rare
entity, it is difficult to conduct prospective studies and
randomized clinical trials to propose the optimum
treatment regimen. Before such a regimen can be
devised, therapy should be decided based on the
activity, effectiveness, and toxicity of these agents for
each individual patient.
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